Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: April 13, 2025

Meplazumab, a humanized CD147 antibody, showed favorable safety and clinical benefits in phase 1 2/3 seamless studies. Further evaluation of its therapeutic efficacy patients with severe COVID-19 is needed. In this 3 add-on study, we randomized 1:1 ratio to receive 0.2 mg/kg meplazumab or placebo via intravenous injection, evaluated within 56 days. Between February 2023 November 2023, 108 were two groups, their baseline characteristics generally balanced. The primary endpoint, 28-day all-cause mortality was 1.96% the group vs 7.69% (P = 0.1703). Supplementary analysis using composite strategy indicated significant reduction compared (3.92% 15.38%, P 0.044). Meplazumab also significantly reduced smoking subjects on day 28 0.047) supplementary analysis. secondary 56-day mortality, 11.54% 0.048), which 3.92% respectively 0.044) by Additional endpoints potential benefits, including increased hospital discharge rates, improved outcomes, viral nucleotide conversion rate. demonstrated good tolerability, no grade ≥ TEAEs observed. These promising results indicate that reduces enhances profile, providing effective specific therapeutics for (the trial registered at ClinicalTrials.gov (NCT05679479)).

Language: Английский

---

Exploiting Host Kinases to Combat Dengue Virus Infection and Disease

Antiviral Research, Journal Year: 2025, Volume and Issue: unknown, P. 106172 - 106172

Published: May 1, 2025

Language: Английский

---

Immunological insights into the re-emergence of human metapneumovirus

Current Opinion in Immunology, Journal Year: 2025, Volume and Issue: 94, P. 102562 - 102562

Published: May 12, 2025

Language: Английский

---